Chemed Corp. 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Chemed Corporation (NYSE: CHE)
Reporting Period: Fiscal Year Ended December 31, 2024
Segments: The Company operates two primary segments: VITAS (hospice and palliative care) and Roto-Rooter (plumbing, drain cleaning, and water restoration).
Key Events: In April 2024, VITAS acquired Covenant Care for $85.0 million. Roto-Rooter completed three franchise acquisitions totaling $12.4 million. The Company repurchased $361.4 million of its own stock during the year.
Key Financial Metrics
| Metric (in thousands, except per share) | 2024 | 2023 |
|---|---|---|
| Service Revenues and Sales | $2,431,287 | $2,264,417 |
| Net Income | $301,999 | $272,509 |
| Diluted Earnings Per Share | $19.89 | $17.93 |
| Adjusted EBITDA | $503,002 | $451,897 |
| Operating Cash Flow | $417,497 | $330,299 |
| Cash and Cash Equivalents (Year End) | $178,350 | $263,958 |
| Long-Term Debt | $0 | $0 |
| Available Credit Facility | $404.5 million | N/A |
Margins: Consolidated gross margin (excluding depreciation) was 35.1% in 2024 versus 35.3% in 2023. VITAS gross margin improved to 25.1% from 22.6%, while Roto-Rooter margin decreased slightly to 52.2% from 52.8%.
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenue increased 7.4% year-over-year. VITAS revenue grew 16.4% driven by a 14.1% increase in days-of-care and a 2.8% increase in Medicare reimbursement rates. Roto-Rooter revenue declined 5.2% due to decreases in job counts across all service lines.
- Profitability: Net income increased 10.8% to $302.0 million. VITAS earnings improved significantly due to higher revenue and the expiration of the temporary retention bonus program. Roto-Rooter earnings declined due to lower revenue and the absence of a one-time tax benefit recorded in 2023.
- Capital Allocation: The Company significantly increased share repurchases to $361.4 million (638,235 shares) compared to $67.7 million in 2023. Capital expenditures were $49.5 million.
- Acquisitions: The $85.0 million Covenant acquisition contributed approximately $31.0–$32.0 million in revenue and $5.0–$6.0 million in net income for 2024.
Guidance, Outlook, and Risks
2025 Guidance:
- VITAS: Revenue (pre-Medicare Cap) estimated to increase 10.5%–11.3%. Average Daily Census (ADC) estimated to increase 8.5%–9.0%. Adjusted EBITDA margin (pre-Medicare Cap) estimated at 18.4%–18.9%. Medicare Cap billing limitations estimated at $9.5 million.
- Roto-Rooter: Revenue growth forecasted at 2.4%–3.0%. Adjusted EBITDA margin expected to be 25.7%–26.3%.
- Consolidated: Adjusted diluted EPS estimated at $24.94–$25.45 (excluding stock option expenses, tax benefits, litigation costs, and discrete items).
Key Risks and Contingencies:
- Regulatory & Medicare Cap: VITAS is highly dependent on Medicare/Medicaid (over 95% of revenue). The Company faces risks from reimbursement rate changes, regulatory audits (OIG), and the Medicare per-beneficiary cap, which requires revenue reductions if limits are exceeded.
- Legal Proceedings: VITAS is involved in an ongoing appeal regarding an OIG audit of elevated level-of-care claims. A $50.3 million deposit was made to preserve appeal rights; a recent Administrative Law Judge ruling favored VITAS on 35 of 36 appealed claims, though CMS may appeal.
- Environmental Liability: The Company has a $1.7 million accrual for environmental cleanup related to the 1991 sale of DuBois Chemicals, with a contingent liability up to $14.9 million.
- Workforce: Both segments face challenges in hiring and retaining skilled labor (nurses for VITAS, plumbers for Roto-Rooter), impacting costs and growth.
Investor Verification Checklist
- Medicare Cap Exposure: Verify the specific impact of the $9.5 million estimated Medicare Cap limitation on 2025 VITAS revenue and the status of the ongoing OIG audit appeal.
- Roto-Rooter Volume Trends: Confirm the drivers behind the 5.2% revenue decline in 2024 and whether the 2025 growth guidance accounts for potential weather-related seasonality or economic headwinds.
- Share Repurchase Sustainability: Assess the Company's ability to sustain the aggressive $361 million repurchase pace in 2025 given the $404.5 million remaining credit facility and operating cash flow.
- Acquisition Integration: Monitor the financial performance of the Covenant Care acquisition to ensure it meets the projected $5–$6 million net income contribution.
- Environmental Contingency: Review updates on the DuBois Chemicals environmental liability to ensure the $1.7 million accrual remains adequate.